Home › Compare › TBMIF vs ABBV
TBMIF yields 133333.33% · ABBV yields 3.06%● Live data
📍 TBMIF pulled ahead of the other in Year 1
Combined, TBMIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TBMIF + ABBV for your $10,000?
Big Tree Carbon Inc., a mineral exploration company, engages in the acquisition, exploration, and development of gold properties in Ontario, Canada. It owns 100% interests in the Richardson Lake gold property consisting of 123 mineral cell and 5-cell multicell mineral claims covering an area of approximately 2,220 hectares; and the Western Fold properties comprises 110 mineral cell claims totaling approximately 2,170 hectares located in Brownstone and Casummit Lake Area mining townships, as well as the Richardson North Extension Gold property consisting of 50 mineral cell claims covering an area of approximately 1,010 hectares. The company also holds 100% interest in the Dancing Man Gold property comprises 654 mineral cell claims totaling approximately 13,280 hectares; the Ranger Lake gold property consisting of 236 mineral cell claims covering an area of approximately 4,790 hectares; and the McFaulds Lake property totaling 450 hectares located in Northern Ontario. In addition, it holds 35% interest in the Bridget Lake property that covers an area of approximately 144 hectares situated in Northern Ontario. The company was formerly known as AurCrest Gold Inc. and changed its name to Big Tree Carbon Inc. in April 2022. Big Tree Carbon Inc. is based in Toronto, Canada.
Full TBMIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.